Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 13;317(1):12.
doi: 10.1007/s00403-024-03509-9.

Safety and efficacy of IL-17 inhibitors in hidradenitis suppurativa: an updated systematic review and meta-analysis including the BE-HEARD trials

Mohammad Haris Ali  1 , Zayed Mohiyuddin  2 , Muiz Khan Tareen  2 , Muhammad Faizan Safdar  2 , Muhammad Talha  3
Affiliations
Review

Safety and efficacy of IL-17 inhibitors in hidradenitis suppurativa: an updated systematic review and meta-analysis including the BE-HEARD trials

Mohammad Haris Ali et al. Arch Dermatol Res. .
No abstract available

Keywords: Bimekizumab; CJM112; Hidradenitis suppurativa; IL-17 inhibitors; Secukinumab.

PubMed Disclaimer

Conflict of interest statement

Declarations Conflict of interest The authors declare that they have no conflict of interest.

References

    1. Kimball AB, Jemec GB, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Bourboulis EJ, Villani AP, Schwinn A, Ruëff F (2023) Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet 401(10378):747–761 - DOI - PubMed
    1. Kimball AB, Jemec GB, Sayed CJ, Kirby JS, Prens E, Ingram JR, Garg A, Gottlieb AB, Szepietowski JC, Bechara FG, Giamarellos-Bourboulis EJ (2024) Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet 403:2504–2519 - DOI - PubMed
    1. Glatt S, Jemec GBE, Forman S, Sayed C, Schmieder G, Weisman J et al (2021) Efficacy and Safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind placebo-controlled randomized clinical trial. JAMA Dermatolog 157(11):1279–1288 - DOI
    1. Kimball AB, Loesche C, Prens EP, Bechara FG, Weisman J, Rozenberg I, Jarvis P, Peters T, Roth L, Wieczorek G, Kolbinger F (2022) IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: combined results from a pre-clinical and phase II proof-of-concept study. Exp Dermatol 31(10):1522–1532 - DOI - PubMed - PMC

LinkOut - more resources